The global prestige beauty market experienced mixed results in the first half of 2013 but the U.S. prestige beauty market posted an 8% gain during the first six months of the year, according to the NPD Group.
Inspired by the open-air markets of Europe, Giant Eagle opened its first Market District food store in Northeast Ohio — a 94,000-square-foot culinary, dining and shopping destination — on Thursday in the Solon Village Shopping Center that the company will staff with a licensed skin care professional and dietitian who will conduct health-and-wellness activities in the store.
Reckitt Benckiser named Alexander Lacik, 48, to the position of president, Reckitt Benckiser North America, effective June 2013. Lacik reports directly to Rob de Groot, EVP Europe and North America, and will be a part of the ENA leadership team.
Sandoz has started a late-stage clinical trial of a biosimilar version of a drug used to treat autoimmune disorders, hoping the results will support its efforts to win regulatory approval in the United States and Europe.
Molson Coors Brewing Company is showcasing a global lineup of product innovations designed to expand its portfolio and provide consumers with variety as the summer season kicks off. The company has planned new releases in Canada, Europe and the United States.
Energizer Holdings had sales of $1.095 billion in second quarter 2013, a 0.5% decrease from second quarter 2012, and $2.28 billion for the first six months of the fiscal year, which ended March 31, also a 0.5% decrease from the same period last year, the company said.
Generic drug maker Hospira marked its fifth year marketing knock-off versions of biotech drugs in Europe Wednesday as it presented at the 2013 Biotechnology Industry Organization International Convention this week.
It's official. During its most recent quarterly conference call with analysts, CVS Caremark revealed what many had anticipated: Its acquisition of privately held Brazilian drug store chain Drogaria Onofre was complete.
Biosimilar medicines have been approved and routinely prescribed in Europe for nearly seven years, and creation of a clear pathway for Food and Drug Administration review and approval of generic versions of bioengineered drugs was enshrined into law in the United States with the passage of the Patient Protection and Affordable Care Act nearly three years ago.
While pressure to grow will drive more large drug makers to pursue mergers and acquisitions, diminished resources and competition from biotech and specialty pharmaceutical companies will challenge their ability to do so, according to a new report.